NTRA

Natera, Inc. | Cotação de Ações

Última atualização21/04/2025, 17:00:01

PreçoUS$ 142,23

Variação (dia)-US$ 5,85 (-3.95%)▼

Min. 52 SemanasUS$ 85,10

Máx. 52 SemanasUS$ 183,00

Capitalização de mercado--

Endereço: 13011 McCallen Pass, Austin, TX, 78753

Telefone: 650 980 9190

Funcionários: 4.424

Natera, Inc.NTRA

US$ 142,23

- 5,854%

21/04/2025 17:00:01

1D 7D 1M 3M 1A Tudo

Visão geral da empresa

Preço atualUS$ 142,23

Valor de mercado--

AberturaUS$ 149,94

Preço máximoUS$ 147,06

Preço mínimoUS$ 140,85

VolumeUS$ 808 mil

Fechamento anteriorUS$ 148,08

Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera molecular residual disease test for assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based genomic profiling test, that provides insight into genomic alterations and biomarkers; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product. It serves independent laboratories, national and regional reference laboratories, medical centers and physician practices, research laboratories, and pharmaceutical companies through its direct sales force, and a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Ações relacionadas

Guardant Health, Inc.

GH ▼0.65% | US$ 36,66

Veracyte, Inc.

VCYT ▼0.52% | US$ 40,58

CareDx, Inc

CDNA ▼0.62% | US$ 21,44

Blueprint Medicines Corporation

BPMC ▲6.10% | US$ 110,05

Twist Bioscience Corporation

TWST ▲1.69% | US$ 47,56

Fique por dentro das últimas notícias do mundo financeiro em nosso Blog

Mantenha-se atualizado com as últimas notícias financeiras em nosso Blog. Publicamos artigos informativos e análises de especialistas para fornecer insights valiosos sobre o cenário financeiro em constante evolução.

Assine nossa newsletter para receber atualizações gratuitas por e-mail

Mantenha-se informado assinando nossa newsletter. Receba atualizações gratuitas por e-mail, incluindo rendimentos, novidades do mercado e insights valiosos. Estamos comprometidos em fornecer informações relevantes diretamente à sua caixa de entrada.

Conheça os Planos e Preços personalizados para acessar recursos exclusivos

Explore nossos Planos e Preços para obter acesso a recursos exclusivos, atendendo às suas necessidades específicas. Oferecemos opções flexíveis para investidores de todos os níveis, garantindo que você tenha as ferramentas certas para otimizar sua estratégia de investimento.